FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Published at www.nejm.org September 10, 2009 (10.1056/NEJMoa0907413)

	Full Text PDF Supplementary Material Preliminary Version Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background A novel influenza A (H1N1) 2009 virus is responsible for the first influenza pandemic in 41 years. A safe and effective vaccine is urgently needed. A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia.

Methods This preliminary report evaluates the immunogenicity and safety of the vaccine 21 days after the first of two scheduled doses. A total of 240 subjects, equally divided into two age groups (<50 years and 50 years), were enrolled and underwent randomization to receive either 15 µg or 30 µg of hemagglutinin antigen by intramuscular injection. We measured antibody titers using hemagglutination-inhibition and microneutralization assays at baseline and 21 days after vaccination. The coprimary immunogenicity end points were the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer, and the factor increase in the geometric mean titer.

Results By day 21 after vaccination, antibody titers of 1:40 or more were observed in 116 of 120 subjects (96.7%) who received the 15-µg dose and in 112 of 120 subjects (93.3%) who received the 30-µg dose. No deaths, serious adverse events, or adverse events of special interest were reported. Local discomfort (e.g., injection-site tenderness or pain) was reported by 46.3% of subjects, and systemic symptoms (e.g., headache) by 45.0% of subjects. Nearly all events were mild to moderate in intensity.

Conclusions A single 15-µg dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions. (ClinicalTrials.gov number, NCT00938639 [ClinicalTrials.gov] .)

Source Information

From Clinical Research and Development, CSL, Parkville, VIC, Australia.

This article (10.1056/NEJMoa0907413) was published on September 10, 2009, at NEJM.org.

Address reprint requests to Dr. Greenberg at Vaccines Clinical Research and Development, CSL, 45 Poplar Rd., Parkville, VIC 3052, Australia, or at michael.greenberg{at}csl.com.au.

Full Text of this Article

This article has been cited by other articles:

• Kotsimbos, T., Waterer, G., Jenkins, C., Kelly, P. M., Cheng, A., Hancox, R. J., Holmes, M., Wood-Baker, R., Bowler, S., Irving, L., Thompson, P., on behalf of the Thoracic Society of Australia and, (2010). Influenza A/H1N1_09: Australia and New Zealand's Winter of Discontent. Am. J. Respir. Crit. Care Med. 181: 300-306 [Abstract] [Full Text]  
• Arguedas, A., Soley, C., Lindert, K. (2010). Responses to 2009 H1N1 Vaccine in Children 3 to 17 Years of Age. NEJM 362: 370-372 [Full Text]  
• Fiore, A. E., Neuzil, K. M. (2010). 2009 Influenza A(H1N1) Monovalent Vaccines for Children. JAMA 303: 73-74 [Full Text]  
• Nolan, T., McVernon, J., Skeljo, M., Richmond, P., Wadia, U., Lambert, S., Nissen, M., Marshall, H., Booy, R., Heron, L., Hartel, G., Lai, M., Basser, R., Gittleson, C., Greenberg, M. (2010). Immunogenicity of a Monovalent 2009 Influenza A(H1N1) Vaccine in Infants and Children: A Randomized Trial. JAMA 303: 37-46 [Abstract] [Full Text]  
• Bishop, J. F., Murnane, M. P., Owen, R. (2009). Australia's Winter with the 2009 Pandemic Influenza A (H1N1) Virus. NEJM 361: 2591-2594 [Full Text]  
• Del Giudice, G., Stittelaar, K. J., van Amerongen, G., Simon, J., Osterhaus, A. D. M. E., Stohr, K., Rappuoli, R. (2009). Seasonal Influenza Vaccine Provides Priming for A/H1N1 Immunization. Sci Transl Med 1: 12re1-12re1 [Full Text]  
• Khazeni, N., Hutton, D. W., Garber, A. M., Hupert, N., Owens, D. K. (2009). Effectiveness and Cost-Effectiveness of Vaccination Against Pandemic Influenza (H1N1) 2009. ANN INTERN MED 0: 0000605-200912150-00157v1-E-157 [Abstract] [Full Text]